These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30545331)

  • 1. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib.
    da Fonseca LG; Marta GN; Braghiroli MIFM; Chagas AL; Carrilho FJ; Hoff PM; Sabbaga J
    BMC Cancer; 2018 Dec; 18(1):1250. PubMed ID: 30545331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
    J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
    Hong YM; Yoon KT; Cho M
    BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib for Treatment of Hepatocellular Carcinoma: A Survival Analysis From the South American Liver Research Network.
    Leathers JS; Balderramo D; Prieto J; Diehl F; Gonzalez-Ballerga E; Ferreiro MR; Carrera E; Barreyro F; Diaz-Ferrer J; Singh D; Mattos AZ; Carrilho F; Debes JD
    J Clin Gastroenterol; 2019 Jul; 53(6):464-469. PubMed ID: 29952857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
    Chen D; Zhao P; Li SQ; Xiao WK; Yin XY; Peng BG; Liang LJ
    Eur J Surg Oncol; 2013 Sep; 39(9):974-80. PubMed ID: 23845703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
    J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
    Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy.
    Shao YY; Wu CH; Lu LC; Chan SY; Ma YY; Yen FC; Hsu CH; Cheng AL
    J Hepatol; 2014 Feb; 60(2):313-8. PubMed ID: 24036008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Xu L; Gao H; Huang J; Wang H; Zhou Z; Zhang Y; Li S; Chen M
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1032-9. PubMed ID: 25639513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib treatment by Child-Pugh score in Latin American patients with hepatocellular carcinoma.
    de Guevara LL; Dagher L; Arruda VM; Nakajima K; Kudo M
    Future Oncol; 2020 Nov; 16(31):2511-2520. PubMed ID: 32783460
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
    El Dika I; Capanu M; Chou JF; Harding JJ; Ly M; Hrabovsky AD; Do RKG; Shia J; Millang B; Ma J; O'Reilly EM; Abou-Alfa GK
    Cancer Med; 2020 Oct; 9(20):7453-7459. PubMed ID: 32841541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
    Iavarone M; Cabibbo G; Piscaglia F; Zavaglia C; Grieco A; Villa E; Cammà C; Colombo M;
    Hepatology; 2011 Dec; 54(6):2055-63. PubMed ID: 21898496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
    Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
    Wada Y; Takami Y; Tateishi M; Ryu T; Mikagi K; Saitsu H
    PLoS One; 2016; 11(1):e0146456. PubMed ID: 26745625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
    Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
    Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
    J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.